TSE:4587Biotechs
PeptiDream (TSE:4587) Valuation Reassessed After 2025 Guidance Cut and Delayed Partnership Milestones
PeptiDream (TSE:4587) just shocked the market by slashing its 2025 guidance, shifting from an expected profit to a projected loss as key partnering milestones slip into 2026.
See our latest analysis for PeptiDream.
The lowered guidance has arrived after a choppy year, with a recent 7 day share price return of 7.5 percent offering only a brief rebound against a deeply negative year to date share price return and a weak 1 year total shareholder return, suggesting momentum is still fragile.
If...